Immix Biopharma, Inc. (IMMX)

Immix Biopharma Statistics

Total Valuation

Immix Biopharma has a market cap or net worth of $143.04 million. The enterprise value is $129.54 million.

Market Cap	143.04M
Enterprise Value	129.54M

Important Dates

The last earnings date was Friday, November 7, 2025, after market close.

Earnings Date	Nov 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Immix Biopharma has 33.58 million shares outstanding. The number of shares has increased by 15.04% in one year.

Current Share Class	33.58M
Shares Outstanding	33.58M
Shares Change (YoY)	+15.04%
Shares Change (QoQ)	+6.48%
Owned by Insiders (%)	20.25%
Owned by Institutions (%)	12.36%
Float	22.86M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	17.19
P/TBV Ratio	17.47
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.13.

Current Ratio	1.53
Quick Ratio	1.47
Debt / Equity	0.13
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -182.55% and return on invested capital (ROIC) is -107.32%.

Return on Equity (ROE)	-182.55%
Return on Assets (ROA)	-66.48%
Return on Invested Capital (ROIC)	-107.32%
Return on Capital Employed (ROCE)	-260.57%
Revenue Per Employee	n/a
Profits Per Employee	-$1.12M
Employee Count	21
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Immix Biopharma has paid $37,243 in taxes.

Income Tax	37,243
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +115.74% in the last 52 weeks. The beta is 0.33, so Immix Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.33
52-Week Price Change	+115.74%
50-Day Moving Average	3.11
200-Day Moving Average	2.37
Relative Strength Index (RSI)	63.84
Average Volume (20 Days)	677,419

Short Selling Information

The latest short interest is 848,278, so 2.53% of the outstanding shares have been sold short.

Short Interest	848,278
Short Previous Month	598,715
Short % of Shares Out	2.53%
Short % of Float	3.71%
Short Ratio (days to cover)	1.13

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-24.05M
Pretax Income	-23.53M
Net Income	-23.56M
EBITDA	-23.84M
EBIT	-24.05M
Earnings Per Share (EPS)	-$0.78

Balance Sheet

The company has $15.95 million in cash and $1.11 million in debt, giving a net cash position of $14.84 million or $0.44 per share.

Cash & Cash Equivalents	15.95M
Total Debt	1.11M
Net Cash	14.84M
Net Cash Per Share	$0.44
Equity (Book Value)	8.26M
Book Value Per Share	0.25
Working Capital	5.73M

Cash Flow

In the last 12 months, operating cash flow was -$14.38 million and capital expenditures -$1.07 million, giving a free cash flow of -$15.45 million.

Operating Cash Flow	-14.38M
Capital Expenditures	-1.07M
Free Cash Flow	-15.45M
FCF Per Share	-$0.46

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immix Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.04%
Shareholder Yield	-15.04%
Earnings Yield	-16.32%
FCF Yield	-10.70%

Analyst Forecast

The average price target for Immix Biopharma is $8.00, which is 87.79% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$8.00
Price Target Difference	87.79%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1